Benefits
Cardiovascular Risk Reduction (Epidemiological)
The dose-response meta-analysis (39 prospective cohorts, 1.5 million individuals, 33,637 CVD cases) showed kaempferol intake is linearly associated with lower risk of cardiovascular disease (CVD). Quercetin showed similar inverse association with coronary heart disease. Population-based evidence is consistent across multiple cohorts; isolated supplement RCTs are sparse.
Anticancer Activity (Mechanistic / Preclinical)
Kaempferol shows broad anticancer activity in vitro — inducing apoptosis in cervical (HeLa), gastric, and other cancer cells; downregulating PI3K/AKT signaling; inhibiting epithelial-mesenchymal transition markers; suppressing matrix metallopeptidase 2 (MMP-2). Mechanism is plausible and broad. Direct anticancer RCTs are absent; epidemiological data is encouraging.
Anti-inflammatory Activity
Kaempferol inhibits NF-κB and AP-1 signaling, MAPK pathways, and pro-inflammatory cytokine production in vitro. Reduces iNOS and COX-2 expression. Underlies cardiovascular and cancer prevention rationales — plus may contribute to broader anti-aging effects.
Antidiabetic Mechanism
Animal studies show kaempferol suppresses IKK/NF-κB hepatic signaling, IRS-1 phosphorylation, and significantly enhances insulin secretion and synthesis. Improves insulin sensitivity in animal diabetes models. Human clinical trials of isolated kaempferol for diabetes are absent; mechanism is plausible.
Antioxidant Activity
Like other flavonols, kaempferol scavenges free radicals and induces endogenous antioxidant systems via Nrf2 activation. Antioxidant capacity is comparable to other major flavonoids (quercetin, myricetin). This underlies many of its other documented activities.
Mechanism of action
NF-κB and AP-1 Pathway Inhibition
Kaempferol inhibits IκB kinase (IKK), preventing NF-κB activation. Also suppresses AP-1 transcription factor activity. This dual transcription factor inhibition reduces expression of inflammatory cytokines, cell proliferation genes, and pro-survival factors — explaining anti-inflammatory and anticancer activities.
PI3K/AKT/mTOR Pathway Modulation
In cancer cells, kaempferol downregulates PI3K/AKT signaling — reducing pro-survival signaling and inducing apoptosis. Same pathway modulation may contribute to insulin signaling effects and longevity-related benefits via mTOR inhibition. Mechanism crosses multiple disease contexts.
Apoptosis Induction in Cancer Cells (Selective)
Kaempferol induces apoptosis in HeLa cervical cancer cells and other cancer types, with relative sparing of normal cells in some studies. Selectivity may relate to cancer cells' altered apoptotic regulation. Translation to clinical anticancer use is mechanism-based, not RCT-validated.
Metastasis Inhibition (EMT Suppression)
Suppresses epithelial-mesenchymal transition (EMT) markers (N-cadherin, E-cadherin, Slug, Snail) and metastasis-related proteins (MMP-2). Provides preclinical rationale for anti-metastatic effects beyond direct cancer-cell apoptosis.
Free Radical Scavenging and Nrf2 Activation
Direct ROS scavenging via 3-hydroxyl group and B-ring catechol structure. Indirect antioxidant effects via Nrf2-mediated induction of phase II detoxification enzymes (HO-1, NQO1, glutathione synthesis). Combined direct + indirect antioxidant effects underlie cardiovascular and anti-aging benefits.
Clinical trials
Foundational review of kaempferol covering plant distribution, pharmacological properties, pharmacokinetics (oral bioavailability, metabolism, plasma levels), and safety. (Calderón-Montaño, Burgos-Morón, Pérez-Guerrero, López-Lázaro 2011, Mini Rev Med Chem)
Comprehensive literature review.
Kaempferol is widely distributed in edible plants (tea, broccoli, cabbage, kale, beans, endive, leek, tomato, strawberries, grapes) and traditional medicinal plants (Ginkgo biloba, Tilia, Equisetum, Moringa, Sophora japonica, propolis). Epidemiological studies show inverse association with cancer and cardiovascular disease risk. Wide range of preclinical activities documented. Establishes the foundational evidence base for kaempferol as a promising bioactive flavonol.
Review of quercetin and kaempferol bioavailability from food sources and potential cardiovascular bioactivity in humans. Covers oral bioavailability of glycosides vs. aglycones, metabolic fate (methyl, glucuronide, sulfate metabolites), and clinical evidence to date. (Dabeek, Marra 2019, Nutrients)
Literature review.
Glucoside conjugates (e.g., from onions) appear to have highest bioavailability. Absorbed flavonols are rapidly liver-metabolized to methyl/glucuronide/sulfate forms — measurable in blood and urine for trial assessments. Optimal effective dose for quercetin's blood pressure / inflammation effects is reported as 500 mg aglycone form; lower doses from plants may be effective due to higher bioavailability of glycosides. Few high-dose kaempferol trials specifically.
Review of epidemiological, preclinical, and clinical studies on kaempferol's cardiovascular protective effects. Mechanisms covered: anti-oxidation, anti-inflammation, antithrombotic activity. (Wang, Chen, Wang, Chen, Liu, Chen, Chen 2022, Pharmacol Ther)
Literature review.
Inverse association between kaempferol-rich food consumption and cardiovascular disease risk across multiple study designs. Mechanisms include endothelial function improvement, NO bioavailability preservation, anti-platelet activity, LDL oxidation inhibition, and inflammation suppression. Establishes a coherent mechanistic basis for the epidemiological findings.